Lebwohl, M.; Warren, R. B.; Imafuku, S.; Bagel, J.; Armstrong, A. W.; Passeron, T.; Banerjee, S.; Colombo, M. J.; Scharnitz, T.; Hoyt, K.; Thaci, D.; Blauvelt, A. Deucravacitinib Long-Term Efficacy Through 4 Years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program. J of Skin 2024, 8, s408.